San Francisco-based biotech Allogene Therapeutics today has filed an application to the regulatory authorities (SEC) to list its stock for trading on the NASDAQ. Considering investors’ interest in the companies working on immuno-oncology, experts estimate that Allogene Therapeutics will rise at least $100m from the IPO, despite the company’s products are still undergoing clinical trials.
In partnership with Servier, Allogene is trying to develop its investigational therapy UCART19 for the treatment of acute lymphoblastic leukemia (ALL). The drug could be launched as early as H2 2019. In addition to UCART19, Allogene has a rich pipeline of immunology therapies.